他非诺喹治疗复发性巴贝虫病:病例系列
本文报告5例复发性巴贝虫病(含既往1例)接受他非诺喹治疗,负荷剂量600 mg,维持剂量每周200 mg或300 mg,较低剂量与田鼠巴贝虫清除延迟相关;4例中3例联合阿托伐醌-氯胍,1例单用他非诺喹未能防止复发。作者认为他非诺喹可作为高度免疫抑制患者复发性田鼠巴贝虫病的辅助治疗。
要点
- 他非诺喹负荷剂量600 mg,维持每周200 mg或300 mg。
- 较低维持剂量与田鼠巴贝虫清除延迟相关。
- 1例单用他非诺喹未能防止复发。
核心结论
- 他非诺喹可作为高度免疫抑制患者复发性田鼠巴贝虫病的辅助治疗。
研究设计与样本
- 病例系列,报告5例复发性巴贝虫病(含既往1例)接受他非诺喹治疗。
- 诊断依据吉姆萨染色薄血涂片镜检或靶向寄生虫18S rRNA基因的实时聚合酶链反应(PCR)。
- 田鼠巴贝虫感染清除通过血涂片和实时PCR确认。
主要发现
- 他非诺喹负荷剂量600 mg,维持剂量为每周200 mg或300 mg;较低剂量与田鼠巴贝虫清除延迟相关。
- 2例在感染清除前停用除他非诺喹外的所有抗菌药物。
- 2例在联合其他抗菌药物使用他非诺喹期间达到清除。
- 上述4例中3例他非诺喹联合阿托伐醌-氯胍使用,其他药物包括阿托伐醌、阿奇霉素和/或克林霉素。
- 1例单用他非诺喹未能防止复发。
临床怎么用
- 作者认为他非诺喹可作为高度免疫抑制患者复发性田鼠巴贝虫病的辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Relapsing babesiosis often occurs in highly immunocompromised patients and has been attributed to the acquisition of resistance against drugs commonly used for treatment such as atovaquone, azithromycin, and clindamycin. Tafenoquine, which is approved for malaria prophylaxis and presumptive antirelapse treatment of Plasmodium vivax malaria, has shown activity against Babesia microti in several animal models of acute infection and in a single human case of relapsing babesiosis. Here, we report 5 cases of relapsing babesiosis treated with tafenoquine, including the previous case, and begin to define the conditions for optimal use of tafenoquine in relapsing babesiosis. METHODS: A definitive diagnosis of babesiosis was made by microscopic examination of Giemsa-stained thin blood smears or a real-time polymerase chain reaction (PCR) that targets the parasite 18S rRNA gene. Clearance of B. microti infection was ascertained by use of blood smear and real-time PCR. RESULTS: Tafenoquine was initiated with a loading dose of 600 mg. A weekly maintenance dose consisted of 200 mg or 300 mg; the lower dose was associated with a delayed clearance of B. microti. In 2 cases, all antimicrobial agents but tafenoquine were discontinued prior to clearance of infection. In 2 other cases, clearance was achieved while tafenoquine was administered along with other antimicrobial agents. In 3 of these 4 cases, tafenoquine was used in combination with atovaquone-proguanil. Other agents included atovaquone, azithromycin, and/or clindamycin. In 1 case, tafenoquine was administered alone and failed to prevent relapse. CONCLUSIONS: Tafenoquine can be a useful adjunct for the treatment of highly immunocompromised patients experiencing relapsing babesiosis caused by B. microti.
引用
- Krause PJ, Rogers R, Shah MK, et al. Tafenoquine for Relapsing Babesiosis: A Case Series. Clin Infect Dis. 2024. PMID: 38814096. doi:10.1093/cid/ciae238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。